) Novel Coronavirus 2019 SARS-CoV-2 (COVID-19) infection is a global pandemic disease that has severely affected the United States. Emerging data suggests that racial and ethnic minority groups are disproportionately affected by COVID-19 and African Americans (AA) are overrepresented among hospitalized patients. The clinical symptoms vary from mild in approximately 80% of cases to critically ill. Established risk factors are age, gender and several comorbidities including cancer. Many other factors in clinical severity remain unexplained. This proposal will leverage remnant biospecimens from laboratory-proven COVID-19 positive individuals at Quest Diagnostics, a national commercial laboratory that has performed over 3.75 million COVID-19 tests and has identified over 298,000 positive cases to date, to study host-genetics of COVID19. We expect to include >7500 samples with whole genome genotyping, performed in collaboration with intramural NCI. While there are no established predictors of severity, certain biomarkers from total blood count have been observed to correlate with worse outcomes. Several studies have reported the role of uncontrolled cytokine release to be correlated with poor outcome. We will incorporate biomarkers such as lymphocyte count, neutrophil count and other inflammation markers to develop a severity score. Using this severity score, we will classify individuals as having mild, severe or critical infection. Biospecimens with de-identified clinical data from Quest and vital status data from the National Death Index in the 28 days period from testing positive, will be utilized to determine whether host genetic factors modify COVID-19 outcomes. We will discover novel genetic variation and clonal hematopoiesis (CH) associated with infection severity, mortality and cytokine storm. Finally, we will compare these novel genetic biomarkers in a cancer cohort of 2,000 individuals from MSKCC to contrast COVID-19 specific outcomes in cancer care. This study represents one of the largest COVID-19 cohorts for genetic association studies. These data will be used to compare genetic diversity and the role it plays in COVID-19 severity and will add to the understanding of constitutional determinants of host immune response to mild and severe viral infection and inflammation.

Public Health Relevance

The novelty of this proposal is leveraging laboratory-proven COVID-19 biospecimens from a leading commercial laboratory in the U.S., Quest Diagnostics, which has performed over 3.75 million COVID-19 tests and has identified over 298,000 positive cases to date, thus ensuring sufficient sample size for our research aims. This will allow us to enrich for African Americans, who are overrepresented in hospitalizations, and utilize biomarkers from total blood count as a severity score to classify individuals as having mild, severe or critical infection. This proposal represents one of the largest COVID-19 cohorts for genetic association and clonal hematopoiesis studied and the stratification proposed will enable a better biological understanding of the disease overall and in cancer patients, including exploring whether genetic susceptibility has a role in disease severity and mortality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-54S4
Application #
10201314
Study Section
Program Officer
Shafik, Hasnaa
Project Start
2020-08-01
Project End
2023-12-31
Budget Start
2020-08-01
Budget End
2020-12-31
Support Year
54
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Blumenthal, Gideon M; Bunn Jr, Paul A; Chaft, Jamie E et al. (2018) Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol 13:1818-1831
Shaffer, Kelly M; Nelson, Christian J; DuHamel, Katherine N (2018) Barriers to participation in a sexual health intervention for men following treatment for rectal and anal cancer. Psychooncology 27:1082-1085
Park, Kay J; Patel, Prusha; Linkov, Irina et al. (2018) Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy. Histopathology 72:766-776
Pianko, Matthew J; Goldberg, Aaron D; Lesokhin, Alexander M (2018) Clinical Development of PD-1 Blockade in Hematologic Malignancies. Cancer J 24:31-35
Navi, Babak B; Marshall, Randolph S; Bobrow, Dylan et al. (2018) Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial. JAMA Neurol 75:379-381
Shah, Sona; Boucai, Laura (2018) Effect of Age on Response to Therapy and Mortality in Patients With Thyroid Cancer at High Risk of Recurrence. J Clin Endocrinol Metab 103:689-697
Goldman, Debra A; Hovinga, Koos; Reiner, Anne S et al. (2018) The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis. J Neurosurg :1-9
Barbetta, Arianna; Schlottmann, Francisco; Nobel, Tamar et al. (2018) Predictors of Nodal Metastases for Clinical T2N0 Esophageal Adenocarcinoma. Ann Thorac Surg 106:172-177
Klein, Mary E; Kovatcheva, Marta; Davis, Lara E et al. (2018) CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell 34:9-20
Gounder, Mrinal M; Solit, David B; Tap, William D (2018) Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. N Engl J Med 378:1945-1947

Showing the most recent 10 out of 8799 publications